Approximately one in four patients died, deteriorated to a higher shock stage, or were transferred for a higher level of care ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced its strategy to secure 7.5 years of U.S. exclusivity ...

Windtree Therapeutics, Inc. announced that it has received guidance from intellectual property and FDA experts regarding a potential strategy for its drug istaroxime, which targets cardiogenic shock.

The outcomes of the SHOCK trial led to a ACC/AHA class 1A recommendation for an early invasive strategy in acute MI complicated by cardiogenic ... ACC/AHA/SCAI 2005 guideline update for ...

If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until ...

avoidance of progression to SCAI Stage D or E cardiogenic shock and need for mechanical cardiac support, time to treatment failure, arrhythmia assessments, days alive and out of the hospital ...

WARRINGTON, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused ...

Initiated enrollment in the global SEISMiC C trial evaluating istaroxime in SCAI Stage C cardiogenic shock—a more severely ... bitartrate), a first-in-class hormone-free, on-demand prescription ...

Initiated enrollment in the global SEISMiC C trial evaluating istaroxime in SCAI Stage C cardiogenic shock—a more severely ill population ... citric acid and potassium bitartrate), a first-in-class ...

Cardiogenic shock happens when the heart suddenly can’t pump enough blood to meet the body’s needs. This leads to a drop in ...